Restriction of HIV and coronavirus infections by the innate immunity protein Shiftless

Project description

Molecular inhibition of viral infectivity

Viruses must hijack cellular machinery to survive, replicate and spread. To maximise the information content of their genomes, viruses have adopted the mechanism of programmed ribosomal frameshifting, which allows parallel translation of multiple protein copies from the same mRNA molecule. The EU-funded RIBOSFL project focuses on the restriction factor Shiftless (SFL), which is known to block virus infectivity by inhibiting ribosomal frameshifting. Researchers aim to study the mechanism of action of SFL, which will pave the way for the design of new antiviral therapeutics. This is of great clinical significance for key pathogens such as HIV and SARS-CoV-2.

Fields of science

• medical and health sciences › health sciences › infectious diseases › RNA viruses › HIV
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antivirals
• natural sciences › biological sciences › microbiology › virology
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › health sciences › infectious diseases › RNA viruses › coronaviruses

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2020 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2020

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Net EU contribution

€ 174 806,40

Address

Hofgartenstrasse 8
80539 Munchen
Germany

Activity type

Research Organisations

Non-EU contribution

€ 0,00

Region

Bayern › Oberbayern › München, Kreisfreie Stadt